Arrivent Biopharma, Inc. (AVBP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 18, 2026, details the results of Arrivent Biopharma, Inc.'s 2026 Annual Meeting of Stockholders. The meeting was conducted via live audio webcast. The Company is an Emerging Growth Company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 46,368,442 shares eligible to vote, a quorum of 33,418,793 shares (72.07%) was present. Stockholders approved the following:
- Election of Directors: James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D. were elected as Class II directors for a three-year term.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It references a definitive proxy statement filed on April 28, 2026, for more complete descriptions of the matters voted upon.
Investor Verification Checklist
- Verify the specific vote counts for director James Healy, who received a significant number of "Withhold Authority" votes (11,527,650) compared to "For" votes (18,058,285).
- Confirm the Company's status as an Emerging Growth Company and any associated reporting exemptions.
- Review the definitive proxy statement (Schedule 14A) filed on April 28, 2026, for detailed background on the director nominees and auditor selection.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.